With Phase III trials for triglyceride-lowering drug AMR101 (ethyl icosapentate) nearly complete, Amarin Corp. plc raised $91.2 million in a public offering of American Depository Shares.
With published data in hand and preclinical studies underway, Rose Pharmaceuticals is raising money to advance GsMTx4, a nontoxic peptide from spider venom intended to slow muscle degradation in Duchenne's muscular dystrophy.
Shares of Inspire Pharmaceuticals Inc. fell 58.7 percent Monday after the firm said cystic fibrosis drug denufosol failed to meet its primary and secondary endpoints in a Phase III trial.
As BioWorld Insight readers know, our "Word on the Street" column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports and some overheard at conferences.
The long-standing relationship between drug developers and academia is changing, with big pharma seeking broader and more direct access to innovative research being done at universities. But as the captains of the drug industry cozy up to the ivory towers, it remains to be seen what role the venture capitalists and biotechs that have historically served as middle-men between these two parties will play.
At a time when many venture capitalists are predicting a contraction of their industry, three biotech veterans have launched a new firm, Longwood Founders Management LLC, and closed an $85 million inaugural fund.
The current initial public offering (IPO) window has not proven particularly welcoming for specialty pharmaceutical firms, but that didn't stop Supernus Pharmaceuticals Inc. from joining the queue with a $100 million filing.
